Akero Therapeutics, Inc.

DB:0K4 Stock Report

Market Cap: €2.1b

Akero Therapeutics Valuation

Is 0K4 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0K4 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0K4's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0K4's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0K4?

Key metric: As 0K4 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0K4. This is calculated by dividing 0K4's market cap by their current book value.
What is 0K4's PB Ratio?
PB Ratio3x
BookUS$738.33m
Market CapUS$2.17b

Price to Book Ratio vs Peers

How does 0K4's PB Ratio compare to its peers?

The above table shows the PB ratio for 0K4 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.9x
BIO3 Biotest
2x29.3%€1.3b
FYB Formycon
1.5x31.5%€857.2m
HPHA Heidelberg Pharma
3x-33.0%€105.8m
2INV 2invest
1xn/a€62.7m
0K4 Akero Therapeutics
3x6.4%€2.2b

Price-To-Book vs Peers: 0K4 is expensive based on its Price-To-Book Ratio (3x) compared to the peer average (1.9x).

Price to Book Ratio vs Industry

How does 0K4's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
0K4 3.0xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0K4 is expensive based on its Price-To-Book Ratio (3x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is 0K4's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0K4 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0K4's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0K4 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€29.55
€45.58
+54.2%
18.5%€61.37€33.05n/a11
Nov ’25€28.25
€42.54
+50.6%
18.3%€55.37€27.68n/a10
Oct ’25€25.52
€41.60
+63.0%
18.3%€54.14€27.07n/a10
Sep ’25€24.06
€42.18
+75.3%
18.3%€54.89€27.45n/a10
Aug ’25€24.48
€41.30
+68.7%
16.6%€51.91€27.81n/a9
Jul ’25€21.69
€41.40
+90.9%
16.6%€52.03€27.87n/a9
Jun ’25€16.81
€41.50
+146.9%
17.0%€51.50€27.59n/a8
May ’25€18.23
€44.59
+144.6%
17.0%€55.39€28.16n/a8
Apr ’25€22.60
€47.07
+108.3%
11.1%€55.11€38.58n/a8
Mar ’25€25.00
€39.91
+59.6%
22.8%€55.37€30.45n/a8
Feb ’25€19.90
€39.53
+98.6%
23.1%€55.31€30.42n/a8
Jan ’25€21.60
€39.53
+83.0%
23.1%€55.31€30.42n/a8
Dec ’24€15.30
€39.53
+158.3%
23.1%€55.31€30.42n/a8
Nov ’24€11.20
€41.36
+269.3%
20.8%€56.98€31.34€28.259
Oct ’24€45.60
€63.57
+39.4%
10.6%€77.72€55.25€25.529
Sep ’24€45.80
€58.35
+27.4%
16.7%€76.73€45.30€24.068
Aug ’24€39.40
€55.98
+42.1%
13.5%€65.16€44.68€24.487
Jul ’24€41.00
€55.98
+36.5%
13.5%€65.16€44.68€21.697
Jun ’24€41.60
€54.47
+30.9%
12.3%€64.47€44.21€16.817
May ’24€39.60
€54.33
+37.2%
12.5%€64.15€43.99€18.237
Apr ’24€34.60
€53.01
+53.2%
11.3%€59.92€44.25€22.606
Mar ’24€42.80
€51.69
+20.8%
12.5%€59.82€44.17€25.006
Feb ’24€45.40
€51.69
+13.9%
12.5%€59.82€44.17€19.906
Jan ’24€50.00
€48.97
-2.1%
15.2%€60.28€37.67€21.606
Dec ’23€44.40
€50.21
+13.1%
14.0%€63.85€39.90€15.306
Nov ’23€42.60
€49.65
+16.5%
19.5%€63.69€30.82€11.206

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.8b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$15.65

7D

-3.7%

1Y

76.2%

Collegium Pharmaceutical

US$1.0b

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.60

7D

5.7%

1Y

27.6%

Pharming Group

€491.5m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.70

7D

-0.7%

1Y

-34.1%